References

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

10.1097/jto.0b013e318206a221 · 2011 · External reference

The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 Classification

10.1097/jto.0000000000000630 · 2015 · External reference

10.1097/jto.0b013e318290868f

10.1097/jto.0b013e318290868f · 2013 · External reference

The 2021 WHO classification of lung tumors: impact of advances since 2015

10.1016/j.jtho.2021.11.003 · 2022 · External reference

PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 ihc assay comparison project

10.1016/j.jtho.2016.11.2228 · 2017 · External reference

Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart

10.1097/jto.0000000000000663 · 2015 · External reference

PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project

10.1016/j.jtho.2018.05.013 · 2018 · External reference

The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming Eighth Edition of the TNM classification of lung cancer

10.1016/j.jtho.2016.03.025 · 2016 · External reference

A grading system for invasive pulmonary adenocarcinoma: a proposal from the International Association for the Study of Lung Cancer Pathology Committee

10.1016/j.jtho.2020.06.001 · 2020 · External reference

10.1016/j.jtho.2017.12.001

10.1016/j.jtho.2017.12.001 · 2018 · External reference

IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy

10.1016/j.jtho.2020.01.005 · 2020 · External reference

The International Association for the Study of Lung Cancer, Lung Cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer

10.1016/j.jtho.2015.10.008 · 2016 · External reference

Best practices recommendations for diagnostic immunohistochemistry in lung cancer

10.1016/j.jtho.2018.12.005 · 2019 · External reference

The 2015 World Health Organization classification of tumors of the thymus: continuity and changes

10.1097/jto.0000000000000654 · 2015 · External reference

The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?

10.1016/j.jtho.2021.10.010 · 2022 · External reference

The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification

10.1016/j.jtho.2015.11.005 · 2016 · External reference

The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification

10.1016/j.jtho.2021.12.014 · 2022 · External reference

The 2015 WHO classification of tumors of the heart and pericardium

10.1016/j.jtho.2015.11.009 · 2016 · External reference

The 2021 WHO classification of tumors of the heart

10.1016/j.jtho.2021.10.021 · 2022 · External reference

Unresolved reference

2015 · External reference

Unresolved reference

2021 · External reference

Small adenocarcinoma of the lung. Histologic characteristics and prognosis

10.1002/1097-0142(19950615)75:12<2844::aid-cncr2820751209>3.0.co;2-# · 1995 · External reference

Unresolved reference

1999 · External reference

Unresolved reference

2004 · External reference

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis

10.1097/pas.0b013e31815cb162 · 2008 · External reference

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage i cases

10.1038/modpathol.2010.232 · 2011 · External reference

The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival

10.1200/jco.2011.37.2185 · 2012 · External reference

10.1097/jto.0b013e318221f701

10.1097/jto.0b013e318221f701 · 2011 · External reference

Expansion of the concept of micropapillary adenocarcinoma to include a newly recognized filigree pattern as well as the classical pattern based on 1468 stage I lung adenocarcinomas

10.1016/j.jtho.2019.07.008 · 2019 · External reference

Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas

10.1097/jto.0000000000000486 · 2015 · External reference

10.1016/j.jtho.2024.03.015

10.1016/j.jtho.2024.03.015 · 2024 · External reference

Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification

10.5858/arpa.2012-0264-ra · 2013 · External reference

Comprehensive next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intrapulmonary metastases: comparison with standard histopathologic approach

10.1158/1078-0432.ccr-19-1700 · 2019 · External reference

Pathologic assessment and staging of multiple non-small cell lung carcinomas: a paradigm shift with the emerging role of molecular methods

10.1016/j.modpat.2024.100453 · 2024 · External reference

Differentiating separate primary lung adenocarcinomas from intrapulmonary metastases with emphasis on pathological and molecular considerations: recommendations from the international association for the study of lung cancer pathology committee

10.1016/j.jtho.2024.11.016 · 2025 · External reference

Genomic staging of multifocal lung squamous cell carcinomas is independent of the comprehensive morphologic assessment

10.1016/j.jtho.2023.09.275 · 2024 · External reference

Defining morphologic features of invasion in pulmonary nonmucinous adenocarcinoma with lepidic growth: a proposal by the International Association for the Study of Lung Cancer Pathology Committee

10.1016/j.jtho.2022.11.026 · 2023 · External reference

Preinvasive lesions of the bronchus

10.1097/jto.0b013e31819667bd · 2009 · External reference

Fibrous stroma is associated with poorer prognosis in lung squamous cell carcinoma patients

10.1097/jto.0b013e318229189d · 2011 · External reference

Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes

10.1097/jto.0000000000000253 · 2014 · External reference

A grading system for resected invasive squamous cell carcinoma of the lung: a multi-institutional study by the IASLC pathology committee

10.1016/j.jtho.2025.09.1761 · 2026 · External reference

Genetic changes in squamous cell lung cancer: a review

10.1097/jto.0b013e31824cc334 · 2012 · External reference

FGFR1 amplification in squamous cell carcinoma of the lung

10.1097/jto.0b013e31826aed28 · 2012 · External reference

Prognostic impact of immune microenvironment in lung squamous cell carcinoma: tumor-infiltrating CD10+ neutrophil/CD20+ lymphocyte ratio as an independent prognostic factor

10.1097/jto.0000000000000617 · 2015 · External reference

ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma

10.1097/jto.0b013e31824c9485 · 2012 · External reference

Pulmonary pleomorphic carcinoma: diagnosis using small biopsy specimens

10.1097/jto.0b013e3181e8f1aa · 2010 · External reference

Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis

10.1097/jto.0b013e3181ce3e3c · 2010 · External reference

Distinct clinicogenomic features and immunotherapy associations in pulmonary sarcomatoid carcinoma: a multicenter retrospective study

10.1016/j.jtho.2025.07.121 · 2025 · External reference

Deep sequencing analysis reveals that KRAS mutation is a marker of poor prognosis in patients with pulmonary sarcomatoid carcinoma

10.1016/j.jtho.2016.04.020 · 2016 · External reference

Response to crizotinib and clinical outcome in ALK-rearranged pulmonary pleomorphic carcinoma

10.1097/jto.0000000000000450 · 2015 · External reference

Synergistic activation upon MET and ALK coamplification sustains targeted therapy in sarcomatoid carcinoma, a deadly subtype of lung cancer

10.1016/j.jtho.2016.01.009 · 2016 · External reference

Long-term survival in two cases of resected gastric metastasis of pulmonary pleomorphic carcinoma

10.1097/jto.0b013e31817c925c · 2008 · External reference

Immune checkpoint inhibitor monotherapy for patients with pulmonary sarcomatoid carcinoma-the optimal therapeutic strategy for this rare lung cancer subtype?

10.1016/j.jtho.2025.08.021 · 2025 · External reference

Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling

10.1016/j.jtho.2017.03.005 · 2017 · External reference

SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas

10.1016/j.jtho.2019.10.023 · 2020 · External reference

Soft tissue sarcomas of the chest wall

10.1097/jto.0b013e3181a97da3 · 2009 · External reference

Comparison of risk stratification models to predict recurrence and survival in pleuropulmonary solitary fibrous tumor

10.1016/j.jtho.2018.05.040 · 2018 · External reference

Better prognostic models may result in improved patient selection for adjuvant therapies after complete resection of solitary fibrous tumors of the pleura

10.1097/jto.0000000000000556 · 2015 · External reference

Initial chemotherapy for locally advanced and metastatic nut carcinoma

10.1016/j.jtho.2023.12.022 · 2024 · External reference

Association between congenital lung malformations and lung tumors in children and adults: a systematic review

10.1016/j.jtho.2016.06.023 · 2016 · External reference

Giant alveolar adenoma causing severe dyspnoea

10.1097/jto.0b013e3181d95ca5 · 2010 · External reference

Solitary papillomas of the lower airways: epidemiological, clinical, and therapeutic data during a 22-year period and review of the literature

10.1097/jto.0b013e3182468d06 · 2012 · External reference

Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond alk gene rearrangements

10.1016/j.jtho.2018.12.003 · 2019 · External reference

Pneumonectomy-sparing NSAID therapy for pulmonary inflammatory myofibroblastic tumor

10.1097/jto.0000000000000574 · 2015 · External reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

10.1056/nejmoa040938 · 2004 · External reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

10.1126/science.1099314 · 2004 · External reference

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

10.1073/pnas.0405220101 · 2004 · External reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

10.1038/nature05945 · 2007 · External reference

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

10.1016/j.cell.2007.11.025 · 2007 · External reference

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group

10.1016/j.annonc.2024.04.005 · 2024 · External reference

Non-small cell lung cancer, version 6.2015

10.6004/jnccn.2015.0071 · 2015 · External reference

Detection of minimal residual disease using CT-DNA in lung cancer: current evidence and future directions

10.1016/j.jtho.2018.09.022 · 2019 · External reference

Molecular pathology of non-small cell carcinoma

10.1111/his.15080 · 2024 · External reference

Screening for lung cancer in individuals who never smoked: an International Association for the Study of Lung Cancer early detection and screening committee report

10.1016/j.jtho.2021.07.031 · 2022 · External reference

A sensitive ALK immunohistochemistry companion diagnostic test identifies patients eligible for treatment with crizotinib

10.1016/j.jtho.2017.01.020 · 2017 · External reference

Emerging targeted therapies for her2-mutant NSCLC

10.1016/j.jtho.2026.103899 · 2026 · External reference

MET alterations in NSCLC-current perspectives and future challenges

10.1016/j.jtho.2022.10.015 · 2023 · External reference

Targeting met in EGFR-mutated NSCLC

10.1016/j.jtho.2026.103711 · 2026 · External reference

Trastuzumab deruxtecan in patients with HER-2-overexpressing NSCLC: results from part 1 of the open-label, multicenter, phase 1b Destiny Lung 03 Trial

10.1016/j.jtho.2025.12.080 · 2026 · External reference

A remarkable year for NSCLC: seven new FDA approvals in 2025 across molecular targets

10.17305/bb.2026.13832 · 2026 · External reference

Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes

10.1016/j.jtho.2019.06.002 · 2019 · External reference

PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee

10.1016/j.jtho.2019.12.107 · 2020 · External reference

Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma

10.1016/j.jtho.2016.06.006 · 2016 · External reference

Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee

10.1016/j.jtho.2022.09.109 · 2022 · External reference

Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?

10.1097/jto.0000000000000526 · 2015 · External reference

The PD-L1 immunohistochemistry biomarker: two steps forward, one step back?

10.1016/j.jtho.2018.01.020 · 2018 · External reference

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

10.1038/s41379-019-0327-4 · 2020 · External reference

Digital versus manual PD-L1 scoring in advanced NSCLC from the IMpower110 and IMpower150 trials

10.1016/j.jtho.2025.07.131 · 2025 · External reference

Antibody-drug conjugates for the therapy of thoracic malignancies

10.1016/j.jtho.2018.11.034 · 2019 · External reference

Antibody-drug conjugates in lung cancer: recent advances and implementing strategies

10.1200/jco.23.00013 · 2023 · External reference

MTAP expression by immunohistochemistry: a novel biomarker in NSCLC

10.1016/j.jtho.2025.08.014 · 2026 · External reference

The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee

10.1016/j.jtho.2020.05.019 · 2020 · External reference

Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification

10.5858/arpa.2012-0263-ra · 2013 · External reference

Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing

10.1055/s-0031-1272866 · 2011 · External reference

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza

10.1183/16000617.0007-2017 · 2017 · External reference

Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists

10.1111/his.15078 · 2024 · External reference

NSCLC subtyping in conventional cytology: results of the International Association for the Study of Lung Cancer Cytology Working Group survey to determine specific cytomorphologic criteria for adenocarcinoma and squamous cell carcinoma

10.1016/j.jtho.2022.02.013 · 2022 · External reference

The World Health Organization reporting system for lung cytopathology

10.1159/000527580 · 2023 · External reference

Immunocytochemistry for predictive biomarker testing in lung cancer cytology

10.1002/cncy.22137 · 2019 · External reference

The updated College of American Pathologists principles of analytic validation of immunohistochemical assays: a step forward for cytopathology

10.1002/cncy.22818 · 2024 · External reference

Tissue management in precision medicine: what the pathologist needs to know in the molecular era

10.3389/fmolb.2022.983102 · 2022 · External reference

Challenges to the effectiveness of next-generation sequencing in formalin-fixed paraffin-embedded tumor samples for non-small cell lung cancer

10.1016/j.anndiagpath.2023.152249 · 2024 · External reference

Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLC

10.1016/j.jtho.2024.03.010 · 2024 · External reference

Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the International Association for the Study of Lung Cancer

10.1016/j.jtho.2024.06.010 · 2024 · External reference

Neoadjuvant targeted therapy in resectable NSCLC: current and future perspectives

10.1016/j.jtho.2023.07.006 · 2023 · External reference

International Association for the Study of Lung Cancer study of reproducibility in assessment of pathologic response in resected lung cancers after neoadjuvant therapy

10.1016/j.jtho.2023.07.017 · 2023 · External reference

Machine learning assessment of pathologic response in lung cancer resections after neoadjuvant therapy—IASLC MPR Project

10.1016/j.jtho.2026.103953 · 2026 · External reference

Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with NSCLC: results from the LCMC3 study

10.1016/j.jtho.2023.12.010 · 2024 · External reference

IASLC mutidisciplinary recommendations for pathological response evaluation of resected lymph nodes after neoadjuvant therapy in NSCLC

10.1016/j.jtho.2025.09.1133 · 2025 · External reference

IASLC update on classification of pulmonary neuroendocrine neoplasms

10.1016/j.jtho.2026.103977 · 2026 · External reference

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

10.1038/s41379-018-0110-y · 2018 · External reference

Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice

10.1097/jto.0000000000000092 · 2014 · External reference

Clinical-pathologic challenges in the classification of pulmonary neuroendocrine neoplasms and targets on the horizon for future clinical practice

10.1016/j.jtho.2021.05.020 · 2021 · External reference

Identification of defined molecular subgroups on the basis of immunohistochemical analyses and potential therapeutic vulnerabilities of pulmonary carcinoids

10.1016/j.jtho.2024.11.018 · 2025 · External reference

The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases

10.1016/j.jtho.2016.12.004 · 2017 · External reference

SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization

10.1016/j.jtho.2020.09.009 · 2020 · External reference

POU2F3 in SCLC: clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC

10.1016/j.jtho.2022.06.004 · 2022 · External reference

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

10.1016/j.ccell.2020.12.014 · 2021 · External reference

The rare YAP1 subtype of SCLC revisited in a biobank of 39 circulating tumor cell patient derived explant models: a brief report

10.1016/j.jtho.2020.07.008 · 2020 · External reference

YAP1 defines an emergent, plastic population of relapsed small cell lung cancer

10.1016/j.jtho.2026.103730 · 2026 · External reference

Antibody–drug conjugates in SCLC: DLL3, B7-H3, TROP2, and beyond

10.1016/j.jtho.2026.103726 · 2026 · External reference

RB tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct RB-proficient subset

10.1158/1078-0432.ccr-22-1115 · 2022 · External reference

Chromothripsis-mediated small cell lung carcinoma

10.1158/2159-8290.cd-24-0286 · 2025 · External reference

Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis

10.21037/tlcr.2020.02.13 · 2020 · External reference

Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets

10.1158/1078-0432.ccr-15-2946 · 2016 · External reference

KRAS G12C inhibition with sotorasib in advanced solid tumors

10.1056/nejmoa1917239 · 2020 · External reference

Therapeutic effects of an alk inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion

10.1016/j.resinv.2024.09.013 · 2024 · External reference

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review

2023 · External reference

BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas

10.1016/j.jtho.2016.12.019 · 2017 · External reference

New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the International Mesothelioma Panel from the Mesopath Reference Center

10.1016/j.jtho.2018.04.023 · 2018 · External reference

Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from the Mesopath Reference Center

10.1016/j.jtho.2020.01.025 · 2020 · External reference

EUROCAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach

10.1016/j.jtho.2019.08.2506 · 2020 · External reference

Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database

10.1097/jto.0b013e31826915f1 · 2012 · External reference

Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center

10.1097/jto.0b013e31815608d9 · 2007 · External reference

Localized malignant pleural mesothelioma: report of two cases

10.1097/jto.0b013e3181a8c874 · 2009 · External reference

Unresolved reference

2026 · External reference

Moving beyond morphology: toward a morpho-molecular classification of pleural mesothelioma

10.1016/j.jtho.2026.01.003 · 2026 · External reference

Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma

10.1097/jto.0b013e318211127a · 2011 · External reference

Molecular characterization of pleomorphic mesothelioma: a multi-institutional study

10.1038/s41379-021-00900-z · 2022 · External reference

Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal

10.1016/j.jtho.2018.07.002 · 2018 · External reference

Improving the accuracy of mesothelioma diagnosis in China

10.1016/j.jtho.2016.12.006 · 2017 · External reference

High incidence of somatic bap1 alterations in sporadic malignant mesothelioma

10.1097/jto.0000000000000471 · 2015 · External reference

BRCA1-associated protein 1 (bap1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study

10.1016/j.jtho.2016.06.020 · 2016 · External reference

Clinical and pathologic phenotyping of mesotheliomas developing in carriers of germline BAP1 mutations

10.1016/j.jtho.2025.06.020 · 2025 · External reference

The role of germline mutations in thoracic malignancies: between myth and reality

10.1016/j.jtho.2023.05.028 · 2023 · External reference

Anaplastic lymphoma kinase gene rearrangement in children and young adults with mesothelioma

10.1016/j.jtho.2019.11.011 · 2020 · External reference

Malignant mesothelioma in situ: clinical and pathologic implications

10.1016/j.jtho.2020.03.014 · 2020 · External reference

The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma

10.1016/j.jtho.2017.02.013 · 2017 · External reference

Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma

10.1016/j.jtho.2017.09.1968 · 2018 · External reference

Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma

10.1016/j.jtho.2019.03.029 · 2019 · External reference

The interplay between the immune system, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy

10.1016/j.jtho.2023.11.017 · 2024 · External reference

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

10.1038/ng.3520 · 2016 · External reference

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

10.1186/s13073-022-01060-8 · 2022 · External reference

Integrative molecular characterization of malignant pleural mesothelioma

10.1158/2159-8290.cd-18-0804 · 2018 · External reference

EORTC-SPECTRA ARCAGEN study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers

10.1038/s41698-024-00518-9 · 2024 · External reference

Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms

10.1016/j.esmoop.2024.103644 · 2024 · External reference

A subset of malignant mesotheliomas in young adults are associated with recurrent ewsr1/fus-atf1 fusions

10.1097/pas.0000000000000864 · 2017 · External reference

Immune composition and immunotherapy outcomes of mesothelioma with BAP1, CKKN2a, MTAP, and NF2 alterations

10.1016/j.jtho.2025.06.018 · 2025 · External reference

Molecular and immunohistochemical testing in mesothelioma and other mesothelial lesions

10.5858/arpa.2023-0213-ra · 2024 · External reference

Bap1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and mbaits

10.1186/1479-5876-10-179 · 2012 · External reference

Tumour predisposition and cancer syndromes as models to study gene-environment interactions

10.1038/s41568-020-0265-y · 2020 · External reference

A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors

10.1038/ng.3016 · 2014 · External reference

Human thymoma-associated mutation of the GTF2I transcription factor impairs thymic epithelial progenitor differentiation in mice

10.1038/s42003-022-04002-7 · 2022 · External reference

A knock-in mouse model of thymoma with the GTF2I l424h mutation

10.1016/j.jtho.2022.08.008 · 2022 · External reference

The integrated genomic landscape of thymic epithelial tumors

10.1016/j.ccell.2018.01.003 · 2018 · External reference

Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis

10.1097/jto.0000000000000397 · 2015 · External reference

Copy number aberrations of BCL2 and CDKN2a/b identified by array-CGH in thymic epithelial tumors

10.1038/cddis.2012.92 · 2012 · External reference

Mutations of epigenetic regulatory genes are common in thymic carcinomas

10.1038/srep07336 · 2014 · External reference

A tuft cell-like signature is highly prevalent in thymic squamous cell carcinoma and delineates new molecular subsets among the major lung cancer histotypes

10.1016/j.jtho.2021.02.008 · 2021 · External reference

Analysis of ASCL1/NEUROD1/POU2F3/YAP1 yields novel insights for the diagnosis of olfactory neuroblastoma and identifies sinonasal tuft cell-like carcinoma

10.1016/j.modpat.2024.100674 · 2025 · External reference

Lymph node dissection in thymic malignancies: implication of the ITMIG lymph node map, TNM stage classification, and recommendations

10.1016/j.jtho.2015.09.001 · 2016 · External reference

ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting

10.1097/jto.0000000000000154 · 2014 · External reference

Thymic carcinomas-a concise multidisciplinary update on recent developments from the thymic carcinoma working group of the International Thymic Malignancy Interest Group

10.1016/j.jtho.2022.01.021 · 2022 · External reference

A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria

10.1097/jto.0000000000000296 · 2014 · External reference

Development of the International Thymic Malignancy Interest Group international database: an unprecedented resource for the study of a rare group of tumors

10.1097/jto.0000000000000269 · 2014 · External reference

The International Association for the Study of Lung Cancer thymic epithelial tumors staging project: an overview of the central database informing revision of the forthcoming (ninth) edition of the TNM classification of malignant tumors

10.1016/j.jtho.2023.07.008 · 2023 · External reference

The impact of thymoma histotype on prognosis in a worldwide database

10.1097/jto.0000000000000393 · 2015 · External reference

The International Association for the Study of Lung Cancer thymic epithelial tumors staging project: proposal for a stage classification for the forthcoming (ninth) edition of the TNM classification of malignant tumors

10.1016/j.jtho.2023.09.002 · 2023 · External reference

Thymomas and thymic carcinomas, version 2.2025, NCCN clinical practice guidelines in oncology

10.6004/jnccn.2025.0027 · 2025 · External reference

Surgical, radiation, and systemic treatments of patients with thymic epithelial tumors: a clinical practice guideline

10.1016/j.jtho.2022.08.007 · 2022 · External reference

10.1016/j.jtho.2023.09.001

10.1016/j.jtho.2023.09.001 · 2023 · External reference

The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: proposal for the T component for the forthcoming (ninth) edition of the TNM classification of malignant tumors

10.1016/j.jtho.2023.08.024 · 2023 · External reference

Assessment of the itmig statement on the WHO histological classification and of the Eighth TNM staging of thymic epithelial tumors of a series of 188 thymic epithelial tumors

10.1016/j.jtho.2017.06.072 · 2017 · External reference

Cancer immunologists scoop medicine Nobel prize

10.1038/d41586-018-06751-0 · 2018 · External reference

Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma

10.1016/j.jtho.2018.04.013 · 2018 · External reference

Paraneoplastic syndromes and thymic malignancies: an examination of the International Thymic Malignancy Interest Group retrospective database

10.1016/j.jtho.2017.11.118 · 2018 · External reference

Molecular classification of neuroendocrine tumors of the thymus

10.1016/j.jtho.2019.04.015 · 2019 · External reference

Impact of positive nodal metastases in patients with thymic carcinoma and thymic neuroendocrine tumors

10.1097/jto.0000000000000660 · 2015 · External reference

Characterization, prognosis, and treatment of patients with locally advanced or metastatic thymic neuroendocrine tumor: A retrospective study of the French GTE, ENDOCAN RENATEN, and RYTHMIC networks

10.1016/j.jtho.2025.04.013 · 2025 · External reference

Neuroendocrine neoplasm update: toward universal nomenclature

10.1530/erc-20-0036 · 2020 · External reference

A high-grade pleomorphic sarcoma in left atrium

10.1097/jto.0000000000000377 · 2015 · External reference

Cardiac sarcomas: an update

10.1097/jto.0b013e3181e59a91 · 2010 · External reference

PRKAR1A in the development of cardiac myxoma: a study of 110 cases including isolated and syndromic tumors

10.1097/pas.0000000000000202 · 2014 · External reference

Prognostic and bioepidemiologic implications of papillary fibroelastomas

10.1016/j.jacc.2015.03.569 · 2015 · External reference

Characterization of the clinical, histopathologic, and immunohistochemical features of large papillary fibroelastomas and their S100-expressing spindle cell component and its potential relationship to cardiac valvular interstitial cells

10.1016/j.carpath.2025.107800 · 2026 · External reference

Identification of candidate genes for histiocytoid cardiomyopathy (HC) using whole genome expression analysis: analyzing material from the hc registry

10.2350/10-05-0826-oa.1 · 2011 · External reference

KRAS mutations in papillary fibroelastomas: a study of 50 cases with etiologic and diagnostic implications

10.1097/pas.0000000000001448 · 2020 · External reference

Benign lipomatous masses of the heart: a comprehensive series of 47 cases with cytogenetic evaluation

10.1016/j.humpath.2014.05.003 · 2014 · External reference

Cardiac angiosarcoma: histopathologic, immunohistochemical, and cytogenetic analysis of 10 cases

10.1016/j.humpath.2016.10.014 · 2017 · External reference

Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas

10.1097/pas.0000000000000184 · 2014 · External reference

Cardiac sarcoma with MDM2 amplification

10.1097/pas.0000000000000275 · 2014 · External reference

Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets

10.1016/j.humpath.2022.02.006 · 2022 · External reference

Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature

10.1038/s41379-021-00874-y · 2021 · External reference

Do “intimal” sarcomas of the heart exist?

10.1097/pas.0000000000000271 · 2014 · External reference